Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABCHIX:BOULS 47 Cash Ratio is 0.09 as of Mar. 2026, which is 50% below its 10-year median of 0.18. GuruFocus rates CHIX:BOULS with a GF Score™ of 47/100 and a GF Value™ of kr49.42. The stock has 2 warning signs investors should review. Among 844 Medical Devices & Instruments companies, Boule Diagnostics AB ranks worse than 92.89% on this metric.
Boule Diagnostics AB has a Cash Ratio of 0.09. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Boule Diagnostics AB's Cash Ratio or its related term are showing as below:
CHIX:BOULs'
s Cash Ratio Range Over the Past 10 Years
Min: 0.08 Med: 0.18 Max: 0.96
Current: 0.09
During the past 13 years, Boule Diagnostics AB's highest Cash Ratio was 0.96. The lowest was 0.08. And the median was 0.18.
CHIX:BOULs's Cash Ratio is ranked worse than 92.89% of 844
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs CHIX:BOULs: 0.09
Boule Diagnostics AB (CHIX:BOULs) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Boule Diagnostics AB Cash Ratio Related Terms
Boule Diagnostics AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BOULS vs ABT, SYK, MDT: Cash Ratio Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (CHIX:BOULS) has a Cash Ratio of 0.09 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Boule Diagnostics AB and its competitors. This is 50% below median its historical median of 0.18. Over the past decade, Boule Diagnostics AB's Cash Ratio has ranged from 0.08 to 0.96. According to the industry distribution chart, Boule Diagnostics AB ranks #784 out of 844 companies in the Medical Devices & Instruments industry, placing it in the top 92.9%.
Is Boule Diagnostics AB's Cash Ratio too high?
Boule Diagnostics AB's current Cash Ratio of 0.09 is 50% below median its 10-year median of 0.18. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 0.96. The Medical Devices & Instruments industry median Cash Ratio is 0.97. Boule Diagnostics AB's value of 0.09 is 90.7% below this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #784 out of 844 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #784 out of 844 companies for Cash Ratio. This places Boule Diagnostics AB in the lower half of its industry. The industry median Cash Ratio is 0.97. Boule Diagnostics AB's value of 0.09 is 90.7% below this benchmark. Historically, Boule Diagnostics AB's own Cash Ratio has ranged from 0.08 to 0.96 over the past decade. While the company's 10-year median is 0.18 vs. the industry median of 0.97, Boule Diagnostics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 844 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current Cash Ratio of 0.09 is 90.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current Cash Ratio is 0.09, which is 50% below median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current Cash Ratio of 0.09. The stock's GF Value™ is kr49.42, compared to a current price of kr26.30 — trading 46.8% below its estimated fair value. The current Cash Ratio is 0.09, which is 50% below median its 10-year median of 0.18 and 90.7% below the Medical Devices & Instruments industry median of 0.97. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current Cash Ratio is 0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr26.30 is trading 46.8% below its estimated GF Value™ of kr49.42.
Key valuation signals for CHIX:BOULS:
Cash Ratio: 0.09 (50% below median its 10-year median of 0.18)
GF Value™: kr49.42 vs. price of kr26.30 (46.8% below fair value)
Industry Position: 90.7% below the Medical Devices & Instruments median (#784 of 844)
No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for CHIX:BOULS
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BOULS has been successfully added to your 
